This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength
by Zacks Equity Research
Bausch Health posts mixed Q1: EPS misses, but revenues beat estimates on strong Salix and Solta growth. Pipeline progress and the raised 2026 view add momentum.
AGENNegative Net Change AMRNPositive Net Change BHCNegative Net Change CSTLPositive Net Change
biotechnology biotechs earnings pharmaceuticals
BMY's Q1 Earnings Top Estimates, Breyanzi, Camzyos Drive Sales
by Zacks Equity Research
Bristol-Myers beats Q1 estimates as strong Growth Portfolio sales and Eliquis demand offset legacy drug declines.
BMYNegative Net Change PFENegative Net Change AGENNegative Net Change AMRNPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs
by Zacks Equity Research
Viking Therapeutics posts a wider Q1 loss as R&D spend jumps on Phase III obesity drug work, while it advances VK2735 studies and preps oral late-stage study.
CPRXPositive Net Change VKTXNegative Net Change CSTLPositive Net Change INDVPositive Net Change
biotechs earnings medical
IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View
by Zacks Equity Research
Ionis tops Q1 estimates and lifts 2026 outlook, drives shares higher as strong drug sales and milestone revenues fuel growth.
AZNNegative Net Change GSKNegative Net Change BIIBNegative Net Change IONSPositive Net Change
biotechs earnings medical pharmaceuticals
TEVA Q1 Earnings Top Estimates, Branded Drugs Drive Revenues, Stock Up
by Zacks Equity Research
Teva beats Q1 earnings and revenue estimates as Austedo, Ajovy and Uzedy fuel growth, lifting shares despite weaker generics performance.
TEVANegative Net Change ALKSNegative Net Change CPRXPositive Net Change INONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength
by Zacks Equity Research
REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.
REGNNegative Net Change SNYNegative Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ABBV Beats on Q1 Earnings & Sales, Raises '26 EPS View
by Zacks Equity Research
AbbVie tops Q1 estimates on strong Rinvoq and Skyrizi sales, lifts 2026 EPS outlook and gains premarket despite continued Humira and Imbruvica declines.
RHHBYPositive Net Change JNJNegative Net Change ABBVNegative Net Change GMABNegative Net Change
biotechs earnings medical pharmaceuticals
ABBV Seeks FDA Nod for Rinvoq Label Expansion in Alopecia Areata
by Zacks Equity Research
AbbVie files for the FDA approval of Rinvoq in alopecia areata, backed by phase III data showing strong hair regrowth and durable results.
ABBVNegative Net Change AMRNPositive Net Change CPRXPositive Net Change CSTLPositive Net Change
biotechs
GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth
by Zacks Equity Research
GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.
GSKNegative Net Change JNJNegative Net Change IONSPositive Net Change SPRONegative Net Change
biotechs earnings
AZN Q1 Earnings and Sales Beat, Key Drugs Offset Generic Pressure
by Zacks Equity Research
AstraZeneca posts Q1 earnings and revenue beat as strong product sales and oncology growth offset generic pressures in key drugs across major markets.
SNYNegative Net Change AZNNegative Net Change MRKPositive Net Change AMGNNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals